[Bone metastases : New aspects of pathogenesis and systemic therapy]
| Autor: | T D, Rachner, F, Jakob, L C, Hofbauer |
|---|---|
| Jazyk: | němčina |
| Rok vydání: | 2016 |
| Předmět: |
Evidence-Based Medicine
Treatment Outcome Bone Density Conservation Agents Dose-Response Relationship Drug Antineoplastic Combined Chemotherapy Protocols Humans Antineoplastic Agents Bone Neoplasms Chemoradiotherapy Adjuvant Dose Fractionation Radiation Denosumab Combined Modality Therapy Drug Administration Schedule |
| Zdroj: | Der Internist. 57(7) |
| ISSN: | 1432-1289 |
| Popis: | The occurrence of bone metastases, in particular secondary to breast and prostate cancer, represents a complex medical condition that is debilitating for affected patients. In order to provide an efficient and personalized therapy, an interdisciplinary treatment approach is mandatory; therefore, systemic pharmacological therapy represents a core element of the overall treatment concept. In terms of pathophysiology, the cancer cells cause a massive disturbance of the local bone microenvironment, which as a rule leads to activation of bone resorbing osteoclasts. In addition to bisphosphonates, which can be considered classical antiresorptive agents, the monoclonal receptor activator of nuclear factor-kappa B ligand (RANKL) antibody denosumab has been in use in clinical practice since 2011. The alpha-emitting radioisotope Alpharadin was also recently approved for the treatment of metastatic prostate cancer. This article provides a summary of the most recent knowledge on the pathogenesis of how cancer cells alter the bone microenvironment as well as a review of established and future systemic treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink